156 related articles for article (PubMed ID: 35481133)
41. The association between fingolimod and mental health outcomes in a cohort of Multiple Sclerosis patients with stress.
Gammoh OS; Al-Smadi A; Alqudah A; Al-Habahbeh S; Weshah F; Ennab W; Al-Shudifat AE; Bjørk MH
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(13):6018-6026. PubMed ID: 37458640
[TBL] [Abstract][Full Text] [Related]
42. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
43. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
44. Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review.
Nazareth T; Friedman HS; Navaratnam P; Herriott DA; Ko JJ; Barr P; Sasane R
BMC Neurol; 2016 Sep; 16(1):187. PubMed ID: 27683214
[TBL] [Abstract][Full Text] [Related]
45. Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.
Eagle T; Stuart F; Chua AS; LaRussa A; Leclaire K; Cook SL; Chitnis T; Weiner HL; Glanz BI; Healy BC
Mult Scler Relat Disord; 2017 Nov; 18():196-201. PubMed ID: 29141809
[TBL] [Abstract][Full Text] [Related]
46. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes
Hunter SF; Thomas FP; Cascione M; Williams IM; Meng X; Schofield L; Weiss JL; Tenenbaum N; Cree BAC;
Mult Scler Relat Disord; 2020 Oct; 45():102346. PubMed ID: 32717684
[TBL] [Abstract][Full Text] [Related]
47. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
English C; Aloi JJ
Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
[TBL] [Abstract][Full Text] [Related]
48. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ;
PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213
[TBL] [Abstract][Full Text] [Related]
49. A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
Duquette P; Yeung M; Mouallif S; Nakhaipour HR; Haddad P; Schecter R
PLoS One; 2019; 14(1):e0210417. PubMed ID: 30640935
[TBL] [Abstract][Full Text] [Related]
50. A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs.
Bowen JD; Kozma CM; Grosso MM; Phillips AL
Mult Scler J Exp Transl Clin; 2018; 4(4):2055217318819031. PubMed ID: 30574342
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
[TBL] [Abstract][Full Text] [Related]
52. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Al Malik Y; Meftah I
Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
[TBL] [Abstract][Full Text] [Related]
53. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
[TBL] [Abstract][Full Text] [Related]
54. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
[TBL] [Abstract][Full Text] [Related]
55. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
56. Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study.
Linker RA; Wendt G
Neurol Ther; 2016 Dec; 5(2):193-201. PubMed ID: 27624575
[TBL] [Abstract][Full Text] [Related]
57. The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.
Freedman MS; Duquette P; Grand'Maison F; Lee L; Vorobeychik G; Lara N; Khurana V; Nakhaipour HR; Schecter R; Haddad P
Curr Med Res Opin; 2019 May; 35(5):767-776. PubMed ID: 30614288
[TBL] [Abstract][Full Text] [Related]
58. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
Hunter SF; Agius M; Miller DM; Cutter G; Barbato L; McCague K; Meng X; Agashivala N; Chin P; Hollander E
J Neurol Sci; 2016 Jun; 365():190-8. PubMed ID: 27206905
[TBL] [Abstract][Full Text] [Related]
59. Initiating oral fingolimod treatment in patients with multiple sclerosis.
Singer BA
Ther Adv Neurol Disord; 2013 Jul; 6(4):269-75. PubMed ID: 23858329
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
